Novartis' Purchase Of Eon Clears FTC; Amide Gets Three Divested Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
The company gains final regulatory approval of its deal for Eon with an agreement to divest three generics to Amide. FTC’s proposed consent order instructs generic subsidiary Sandoz to supply two of the drugs – antidepressant desipramine and muscle relaxant orphenadrine – until Amide receives FDA manufacturing clearance.